Erythromycin Ethylsuccinate

Fermentation is a critical step in both drug and toll manufacturing, as companies look to produce the core compounds that form their eventual products. While it is possible to undertake this in-house, the expertise contract fermentation services provide can improve the quality, affordability, speed and sca...

With patients’ lives at the end of the pipeline, biologics contract manufacturing needs to be safe, reliable and be consistent in supply. The developers of these large molecule drugs, however, are also operating in a highly competitive space. Speed-to-market is imperative, along with efficient processes an...

hen selecting AbbVie Contract Manufacturing, you are partnering with a leading developer and manufacturer focused on accelerating and mitigating risks to program timelines and on efficiently fast-tracking your program to completion. AbbVie’s mAb and ADC state-of-the-art facility and expert scientific team ...

High potency manufacturing is an expanding field with a unique set of challenges. Safety remains a primary concern for those handling cytotoxic drug products, as well as the clinicians and patients down the line. Beyond safety, pharmaceutical companies need to plan ahead for how they will manufacture high ...

Fill-finish syringe manufacturing is one of the last steps in pharmaceutical commercialization. The goal here is efficiency and sterility. Companies don’t want to waste any of their carefully developed product and they don’t want to distribute poor quality prefilled syringes or contaminated formulas. Once ...

For more information contact AbbVie Contract Manufacturing

For more information contact AbbVie Contract Manufacturing

For more information contact AbbVie Contract Manufacturing. 

For more information please contact AbbVie Contract Manufacturing. 

We offer two convenient fill-finish options for parenteral drug products: prefilled syringe and vials. As a leading pharmaceutical partner, we can provide all necessary elements of delivering high-quality parenteral products for clinical and commercial needs.

AbbVie will leverage its know...

AbbVie’s API site has the flexibility to run multiple chemical processes simultaneously to support late development phase to commercial products including highly potent drug containment up to OEL 3A (1 µg/m3). State of the art QC laboratories integrated across a highly experienced team focused on commercia...

Whether you’re developing a new chemical entity or a first-to-market generic, precise dosing and drug delivery is vital for success. Regulatory agencies and clinicians want to see well-characterized, reliable doses with good bioavailability. Patients/consumers often favor a controlled release dosage form, ...

AbbVie, the speciality biopharmaceutical company has once again made headway in the treatment of Parkinson’s disease. 

AbbVie’s Contract Manufacturing business has been serving our partners for more than 40 years. Our contract development and manufacturing capabilities span across 11 production facilities in North America and Europe. Our capabilities are: Aseptic Fill Finish (Vial and Prefilled Syringe) Custom & Bulk API Manufacturing Oral Solid Dose Fermentation Hot Melt Extrusion Potent Biologics Packaging

Following a successful few days in Philadelphia for CPHI North America, I was able to discuss some of the sessions with our expert speakers, gaining a little more insight into the key topics from the event. 

The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). 

Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are already 26 novel drug approvals (at time of writing), for half way through the year this is already a staggering number, showing just how successful the investments into innovations are in the industry. 

AbbVie and Genmab recently received approval from the US FDA for their joint venture, the blood cancer therapy epcoritamab, sold under the brand name EPKINLY.